Zhongguancun (000931.SZ): Buspirone hydrochloride tablets consistency evaluation application accepted

Zhitong Finance App News, Zhongguancun (000931.SZ) announced that the company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. (Beijing Huasu), recently received the “Notice of Acceptance” issued by the State Drug Administration, and the generic consistency evaluation application for buspirone hydrochloride tablets (specifications: 5 mg, 10 mg) was accepted.

Buspirone is the first non-benzodiazepine anxiolytic drug. It is a 5-HT1A (serotonin) receptor agonist. It reduces 5-HT activity that is too high in anxiety through selective binding with 5-HT1A receptors in the brain and produces anxiolytic effects. The biggest advantage of its clinical application is that it has no drug dependency or withdrawal response, and is highly safe. Buspirone hydrochloride tablets are indicated for various anxiety disorders.